Statins in certain patient populations: scientific evidence and algorithms for practicing physicians

Cover Page

Cite item

Full Text

Abstract

Treatment with 3-hydroxy-3-methylglutaryl coenzyme A-reductase inhibitors (statins) is the basis for primary and secondary prevention of atherosclerosis and is regulated by many international and Russian guidelines and consensus. Data from lipid-lowering studies with "hard" endpoints showed that combination therapy can also lead to a further reduction in cardiovascular (CV) risk with the achievement of very low levels of low-density lipoprotein cholesterol (0.5-1 mmol/L) without increasing the risk of side effects. Despite the scientific progress in this field, there are large barriers between the recommendations and the real clinical practice of using statins in our country. As before, even patients with a very high CV risk are prescribed low and medium doses of statins by doctors of various specialties; the possibilities of combination therapy are still poorly realized. This review will provide an analysis of the evidence base, as well as an attempt to harmonize recommendations, expert consensus on optimizing statin therapy in certain patient groups - in primary prevention (low/moderate CV risk), in patients with high/very high CV risk in patients with arterial hypertension and dyslipidemia, as well as in patients with confirmed familial hypercholesterolemia. This publication presents possible algorithms for the use of statins in these categories of patients, which, in the author's opinion, will be useful for practicing physicians in their day-to-day clinical practice.

About the authors

Andrey V. Susekov

Russian Medical Academy of Continuous Professional Education

Email: asus99@mail.ru
д-р мед. наук, проф. Moscow, Russia

References

  1. Ference BA, Ginsberg HN, Graham I, et al. Low density lipoprotein cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic and clinical studies. A Consensus Statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J 2017; 38 (32): 245972. doi: 10.1093/eurheartj/ehx144
  2. Boren J, Chapman MJ, Krauss RM, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J 2020; 41 (24): 2313-30. doi: 10.1093/eurheartj/ehz962
  3. Grundy SM, Stone NJ, Bailey AL, et al. A Repor of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 2019; 73 (24): e285-350. doi: 10.1016/j.jacc.2018.11.003
  4. Authors/Task Force Members; ESC Committee for Practice Guidelines (CPG); ESC National Cardiac Societies 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Atherosclerosis 2019; 290: 140-205. doi: 10.1016/j.atherosclero-sis.2019.08.014
  5. GittA, Lautsch D, Ferriees J, et al. Contemporary data on treatment practices for low-density lipoprotein cholesterol in 6794 patients with stable coronary heart disease across the world. Data in brief 2018; 18: 1937-40.
  6. Ершова А.И., Мешков А.Н., Якушин С.С., и др. Диагностика и лечение боьных с выраженной гиперхолестеринемией в реальной амбулаторно-клинической практике (по данным регистра РЕКВАЗА). Рацион. фармакотерапия в кардиологии. 2014; 10 (6): 612-6
  7. Ахмеджанов Н.М., Небиеридзе Д.В., Сафарян А.С., и др. Анализ распространенности гиперхолестеринемии в условиях амбулаторной практики (по данным исследования АРГО): часть I. Рацион. фармакотерапия в кардиологии. 2015; 11 (3): 252-9
  8. Оганов Р.Г., Кухарчук В.В., Арутюнов Г.П., и др. Сохраняющиеся нарушения показателей липидного спектра у пациентов с дислипидемией, получающих статины, в реальной клинической практике в Российской Федерации (российская часть исследования DYSIS). Кардиоваскулярная терапия и профилактика. 2012; 11 (4): 70-8
  9. Nordestgaard BG, Chapman MJ, Humphries SE, et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease. Eur Heart J 2013; 34 (45): 3478-90a. doi: 10.1093/eurheartj/eht273
  10. Watts GF, Gidding S, Wierzbicki AS. Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation. Int J Cardiol 2014; 171: 309-25.
  11. Akioyamen LE, Genest J, Shan SD, et al. Estimating the prevalence of heterozygous familial hypercholesterolaemia: a systematic review and meta-analysis. BMJ Open 2017; 7: e016461.
  12. Vallejo-Vaz A, Sreenivasa R, Cole D, et al. Familial hypercholesterolaemia: A global call to arms. Atherosclerosis 2015; 243: 257e259.
  13. Vallejo-Vaza AJ, Marcoa M, Stevens AT. Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). Atherosclerosis 2018; 277: 234-55.
  14. Сусеков А.В., Яфарова А.А., Щербакова М.Ю., Мешков А.Н. Регрессия ксантоматоза у 12летнего пациента с гомозиготной формой семейной гиперхолестеринемии: клинический случай. Педиатрия. Consilium Medicum. 2016; 3: 103-8
  15. Зафираки В.К., Космачева Е.Д., Лузакова И.А., и др. Диагностика и лечение гетерозиготной семейной гиперхолестеринемии. Лечеб. дело. 2019; 3: 11-21
  16. Зафираки В.К., Космачева Е.Д.,Захарова И.Н., и др. Гомозиготная семейная гиперхолесте-ринемия:современные аспекты диагностки, патогенеза, диагностики и терапии. Мед. совет. 2018; 17: 253-60.
  17. Susekov A, Meshkov A, Korneva V, et al. Clinical characteristics and LDL-C achievement rates in 506 FH patients from 4 Russian lipid clinics. J Clin Lipidol 2016; 10 (3): 698. doi: 10.1016/j.jacl.2016.03.070
  18. Сусеков А.В., Лугинова З.Г., Горнякова Н.Б., Балахонова Т.В. Замедление прогрессирования мультифокального атеросклероза у больной с первичной гиперхолестеринемией на фоне длительной (16 лет) гиполипидемической терапии. РМЖ. 2020; 10: 29-34
  19. Agatston AS, Janowitz WR, Hildner FJ, et al. Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol 1990; 15 (4): 827-32. doi: 10.1016/0735-1097(90)90282-t
  20. Федотенков И.С., Терновой С.К. Скрининг кальциноза коронарных артерий методом мульти-спиральной компьютерной томографии. Мед. визуализация. 2017; 21 (4): 19-32
  21. Hecht HS. For the Society of Atherosclerosis Imaging. Practice guidelines for electron-beam tomography: a report of the Society of Atherosclerosis Imaging. Am J Cardiol 2000; 86: 705-6.
  22. Ford ES, Ajani UA, Croft JB, et al. Explaining the Decrease in U. S. Deaths from Coronary Disease, 1980-2000. New Eng J Med 2007; 23 (7): 2388-98.
  23. The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH) Authors. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J 2018: 39: 3021-104. doi: 10.1093/eurheartj/ehy339
  24. Бойцов С.А., Баланова Ю.А., Шальнова С.А., и др. Артериальная гипертония среди лиц 2564 лет: распространенность, осведомленность, лечение и контроль. По материалам исследования ЭССЕ. Кардиоваскулярная терапия и профилактика. 2014; 13 (4): 4-14
  25. Бойцов С.А., Деев А.Д., Шальнова С.А. Смертность и факторы риска развития неинфекционных заболеваний в России: особенности, динамика и прогноз.Терапевтический архив. 2017; 89 (1): 5-13
  26. Шальнова С.А., Деев А.Д., Баланова Ю.А., и др. Двадцатилетние тренды ожирения и артериальной гипертонии и их ассоциация в России. Кардиоваскулярная терапия и профилактика. 2017; 16 (4): 4-10
  27. Бойцов С.А., Шальнова С.А., Деев А.Д. Смертность от сердечно-сосудистых заболеваний в Российской Федерации и возможные механизмы ее изменения. Журн. неврологии и психиатрии. 2018; 8: 98-103
  28. Муромцева Г.А., Концевая А.В., Константинов В.В., и др. Распространенность факторов риска неинфекционных заболеваний в российской популяции в 2012-2013 гг. Результаты исследования ЭССЕ-РФ. Кардиоваскулярная терапия и профилактика. 2014; 13 (6): 4-11
  29. Poulter N. In Cardiovascular Disease: Risk Factors and Intervention. Eds: N. Poulter, P. Sever, S. Thom. Oxford: Radcliffe Medical Press, 1993.
  30. DeBacker G, Jankowski P, Kotseva K, et al. Management of dyslipidaemia in patients with coronary heart disease: Results from the ESC-EORP EUROASPIRE V survey in 27 countries. Atherosclerosis 2019;285: 135-46.
  31. Dalal JJ, Padmanabhan TNC, Jain P, et al. LIPITENSION: Interplay between dyslipidemia and hypertension. Indian J Endocrinol Metab 2012; 16 (2).
  32. National Clinical Guideline Centre. National Institute for Health and Care Excellence (NICE) clinical guideline CG181: lipid modification, cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease. Available at: https://www.nice.org.uk/guidance/cg181. Published July 2014. Accessed: 11.01.2021.
  33. National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. The Expert Panel. Arch Intern Med 1988; 148 (1): 36-69.
  34. Lacland DT, Mitchel SV, DAgostino RD, et al. Inclusion of stroke in cardiovascular risk prediction instruments: a statement for healthcare professionals from the American Heart Associ ati on/Ameri can Stroke Association. Stroke 2012; 43 (7): 1998-2027. doi: 10.1161/STR.0b013e31825bcdac
  35. Aboyans V, Ricco JB, Bartelink M, et al. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteriesEndorsed by: the European Stroke Organization (ESO)The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS). Eur Heart J 2018; 39 (9): 763-816. doi: 10.1093/eurheartj/ehx095
  36. Amarenco P, Bogousslavsky J, Callahan A, et al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006; 355 (6): 549-59.
  37. Amarenco P. IAS Congress. Boston, 8 June 2009.
  38. Baigent C, Keech A, Keraney PM. Efficacy and Safety of Cholesterol-Lowering Treatment: Prospective Meta-Analysis of Data From 90,056 Participants in 14 Randomized Trials of Statins. Lancet 2005; 366 (9493): 1267-78.
  39. Cholesterol Treatment Trialists (CTT) Collaborators Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomized trials. Lancet 2010;376: 1670-81.
  40. Cholesterol Treatment Trialists (CTT) Collaborators The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomized trials. Lancet 2012; 380: 581-90.
  41. Cholesterol Treatment Trialists (CTT) Collaborators. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomized trials. Lancet 2015; 385: 1397-405.
  42. Cannon CP, Steinberg BA, Murphy SA, et al. Meta-analysis of cardiovascular outcomes trials comparing Intensive versus Moderate statin therapy. J Am Coll Cardiol 2006; 48: 438-45.
  43. Riisgaard AR, Vestergaard Ch, Vestergaard M, et al. Statins and risk of intracerebral hemorrage in individuals with a history of stroke. Stroke 2020; 51 (4): 1111-9. doi: 10.1161/STROKEAHA.119.027301
  44. Newman C, Tobert J, Jacobson TA, et al. Statin Safety and Associated Adverse Events A Scientific Statement From the American Heart Association. Arterioscler Thromb Vasc Biol 2019; 39: e38-81. doi: 10.1161/ATV.0000000000000073
  45. Mortensen NB, Falk E, Schmidt M. Twenty-Year Nationwide Trends in Statin Utilization and Expenditure in Denmark. Circ Cardiovasc Qual Outcomes. 2017; 10: e003811. doi: 10.1161/CIRCOUTCOMES.117.003811

Copyright (c) 2021 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies